Free Trial
NASDAQ:TLX

Telix Pharmaceuticals (TLX) Stock Price, News & Analysis

Telix Pharmaceuticals logo
$12.09 -0.45 (-3.59%)
As of 12:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Telix Pharmaceuticals Stock (NASDAQ:TLX)

Key Stats

Today's Range
$11.80
$12.50
50-Day Range
$10.82
$17.15
52-Week Range
$10.50
$30.36
Volume
164,879 shs
Average Volume
46,144 shs
Market Capitalization
$4.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.33
Consensus Rating
Buy

Company Overview

Receive TLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TLX Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
Wedbush Reduces Earnings Estimates for Telix Pharmaceuticals
See More Headlines

TLX Stock Analysis - Frequently Asked Questions

Telix Pharmaceuticals' stock was trading at $15.40 at the start of the year. Since then, TLX stock has decreased by 21.4% and is now trading at $12.10.

Telix Pharmaceuticals (TLX) raised $202 million in an initial public offering on Friday, June 14th 2024. The company issued 17,000,000 shares at $11.87 per share.

Top institutional shareholders of Telix Pharmaceuticals include Pier Capital LLC (0.06%), Russell Investments Group Ltd. (0.02%), Jane Street Group LLC (0.01%) and Vanguard Personalized Indexing Management LLC (0.01%).

Shares of TLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
8/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TLX
Previous Symbol
NASDAQ:TLX
CIK
2007191
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$23.00
Low Price Target
$22.00
Potential Upside/Downside
+85.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.99
Current Ratio
2.78
Quick Ratio
2.66

Sales & Book Value

Annual Sales
$516.72 million
Price / Sales
7.89
Cash Flow
$0.11 per share
Price / Cash Flow
106.84
Book Value
$1.12 per share
Price / Book
10.76

Miscellaneous

Outstanding Shares
338,400,000
Free Float
N/A
Market Cap
$4.08 billion
Optionable
N/A
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:TLX) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners